Search Results - "Eisenstein, Barry I"

Refine Results
  1. 1
  2. 2

    Daptomycin: From the Mountain to the Clinic, with Essential Help from Francis Tally, MD by Eisenstein, Barry I., Oleson, Frederick B., Baltz, Richard H.

    Published in Clinical infectious diseases (01-01-2010)
    “…Daptomycin has been approved and successfully launched for the treatment of complicated skin and skin-structure infections caused by gram-positive pathogens…”
    Get full text
    Journal Article Conference Proceeding
  3. 3

    Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections by Eisenstein, Barry I

    Published in Expert opinion on investigational drugs (01-09-2004)
    “…The increasing incidence of serious infections caused by antibiotic-resistant Gram-positive bacteria has led to the development of new spectrum-specific…”
    Get more information
    Journal Article
  4. 4
  5. 5
  6. 6

    The evolution of the regulatory framework for antibacterial agents by Rex, John H., Goldberger, Mark, Eisenstein, Barry I., Harney, Carrie

    Published in Annals of the New York Academy of Sciences (01-09-2014)
    “…The rising tide of antibacterial resistance and the lack of a diverse, vibrant pipeline of novel antibacterial agents is a global crisis that impairs our…”
    Get full text
    Journal Article
  7. 7
  8. 8

    Towards a global definition of responsible antibiotic use: results of an international multidisciplinary consensus procedure by Monnier, Annelie A, Eisenstein, Barry I, Hulscher, Marlies E, Gyssens, Inge C

    Published in Journal of antimicrobial chemotherapy (01-06-2018)
    “…Abstract Background Conducted as part of the Driving Reinvestment in Research and Development and Responsible Antibiotic Use (DRIVE-AB) project, this study…”
    Get full text
    Journal Article
  9. 9

    Development potential of rifalazil by Rothstein, David M, Hartman, Arthur D, Cynamon, Michael H, Eisenstein, Barry I

    Published in Expert opinion on investigational drugs (01-02-2003)
    “…Rifalazil represents a new generation of ansamycins that contain a unique four-ring structure. Originally rifalazil was developed as a therapeutic agent to…”
    Get more information
    Journal Article
  10. 10

    The Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-Structure Infections by Arbeit, Robert D., Maki, Dennis, Tally, Francis P., Campanaro, Edward, Eisenstein, Barry I.

    Published in Clinical infectious diseases (15-06-2004)
    “…Daptomycin is the first available agent from a new class of antibiotics, the cyclic lipopeptides, that has activity against a broad range of gram-positive…”
    Get full text
    Journal Article
  11. 11
  12. 12
  13. 13

    The Polymerase Chain Reaction: A New Method of Using Molecular Genetics for Medical Diagnosis by Eisenstein, Barry I

    Published in The New England journal of medicine (18-01-1990)
    “…THE development of molecular genetics, both as a self-contained field and as a body of techniques broadly useful in biologic investigation, has had a profound…”
    Get full text
    Journal Article
  14. 14

    Detection of Microbial Nucleic Acids for Diagnostic Purposes by Engleberg, N. Cary, Eisenstein, Barry I

    Published in Annual review of medicine (1992)
    “…The last decade has seen an explosion of interest in the use of molecular genetic techniques to diagnose infectious diseases. Specific molecular probes have…”
    Get full text
    Journal Article
  15. 15
  16. 16

    Daptomycin Versus Ciprofloxacin in the Treatment of Complicated Urinary Tract Infection Due to Gram-positive Bacteria by Naber, Kurt G, Eisenstein, Barry I, Tally, Francis P

    “…BACKGROUND:Complicated urinary tract infections (UTIs) due to Gram-positive pathogens are of increasing concern because of steadily emerging resistance to…”
    Get full text
    Journal Article
  17. 17

    Phase Variation of Type 1 Fimbriae in Escherichia coli is under Transcriptional Control by Eisenstein, Barry I.

    “…An operon fusion of the lac genes to those required for synthesis of type 1 fimbriae (pili) has been achieved in a K12 strain of Escherichia coli lysogenized…”
    Get full text
    Journal Article
  18. 18

    Impact of Antibiotic Resistance on the Treatment of Gram-negative Sepsis by Baden, LR, Eisenstein, BI

    Published in Current infectious disease reports (01-10-2000)
    “…Resistance among gram-negative organisms has greatly complicated the care of the septic patient. An understanding of the likely source of infection, the…”
    Get full text
    Journal Article
  19. 19

    New Opportunistic Infections — More Opportunities by Eisenstein, Barry I

    Published in The New England journal of medicine (06-12-1990)
    “…Many of the infectious diseases that occur in patients with the acquired immunodeficiency syndrome (AIDS) are caused by common pathogenic microbes, such as…”
    Get full text
    Journal Article
  20. 20

    Human tissue research in the genomic era of medicine: balancing individual and societal interests by Ashburn, T T, Wilson, S K, Eisenstein, B I

    Published in Archives of internal medicine (1960) (11-12-2000)
    “…Advances in DNA sequencing technology and in our understanding of the human genome are ushering in a new era of genomic medicine, one with dramatic potential…”
    Get more information
    Journal Article